Drug Profile
Fixed-dose combination liver disorder therapeutic - Waterstone Pharmaceuticals
Latest Information Update: 28 Dec 2017
Price :
$50
*
At a glance
- Originator Waterstone Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Liver disorders
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for phase-I development in Liver-disorders in China
- 05 Nov 2014 Phase-I clinical trials in Liver disorders in China (unspecified route)